Valuation: EnteroMedics Inc

Market Cap 15.16M 13.27M 12.25M 11.44M 21.54M 1.43B 22.03M 147M 56.93M 707M 56.93M 55.68M 2.45B P/E 2026 *
-3.06x
P/E 2027 * -2.36x
Enterprise Value 15.16M 13.27M 12.25M 11.44M 21.54M 1.43B 22.03M 147M 56.93M 707M 56.93M 55.68M 2.45B EV / Sales 2026 *
101x
EV / Sales 2027 * 60.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 131K 121K 113K 213K 14.18M 218K 1.46M 563K 7M 563K 551K 24.29M 250K 219K 202K 189K 355K 23.64M 363K 2.43M 939K 11.66M 939K 918K 40.48M
Net income -4.89M -4.28M -3.95M -3.69M -6.95M -462M -7.11M -47.57M -18.36M -228M -18.36M -17.96M -792M -7.77M -6.8M -6.28M -5.86M -11.04M -735M -11.29M -75.57M -29.17M -362M -29.18M -28.54M -1.26B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-